• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24104 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Drug-eluting balloon for the treatment of coronary stenosis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilation catheter for the transurethral treatment of urethral strictures - Assessment according to §137h Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilation catheter for the transurethral treatment of urethral strictures - Assessment according to §137h Social Code Book V - Third addendum to Commission H20-02]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilatation catheter for transurethral treatment of urethral strictures - Addendum to commission H20-02]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon catheter for the transurethral treatment of urethral strictures - Second addendum to commission H20-02]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug treatment of hypertension - update search (rapid report)]
2016     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Drug treatment of children with respiratory tract infections - a scoping review]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Drug treatment of ADHD (Attention Deficit/Hyperactivity Disorder) in adults in Germany]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug combination of emtricitabine, rilpivirine and tenofovir disoproxil (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Drotrecogin alfa in the treatment of severe sepsis]
2011     Haute Autorite de sante (HAS) [Dressings: indications and recommended uses]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Second addendum to commission A21-84]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V - Addendum]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Addendum to Project A23-143]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine (HIV infection in adolescents) - Benefit assessment according to §35a Social Code Book V]
2009     The Swedish Council on Health Technology Assessment (SBU) [Dopaminergic agents in treating restless legs syndrome]
1999     Basque Office for Health Technology Assessment (OSTEBA) [Domiciliary oxygen therapy]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/abacavir/lamivudine (HIV infection in children) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/abacavir/lamivudine - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dolutegravir, Abacavir and Lamivudine (Triumeq®) in HIV infection]
2020     National Committee for Technology Incorporation (CONITEC) [Dolutegravir for the treatment of pregnant women living with HIV]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection) - Addendum to commission A17-11]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection in children aged >= 4 weeks to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2002     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [DMARD therapy of rheumatoid arthritis, systematic review of the clinical and economic literature]
2011     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Dissemination of HTA products. New lines of action]
2020     National Authority for Assessment and Accreditation in Healthcare (INEAS) [Disinfection chambers/tunnels in the context of COVID-19 pandemic]
2013     Norwegian Knowledge Centre for the Health Services (NOKC) [Discharging patients with chronic disease: effect of various forms of cooperation between hospital and the community health service]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Diroximel fumarate (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Direct-acting oral anticoagulants for postoperative thrombosis prophylaxis]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dipyridamole and aspirin for secondary prevention after stroke or TIA]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl-peptidase 4 inhibitors in patients with prediabetes or metabolic syndrome]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl peptidase-4 inhibitors as treatment for diabetes mellitus]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl peptidase-4 (dpp4) inhibitors in diabetes mellitus]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Diode laser vaporization in benign prostatic hyperplasia]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dinutuximab for patients with high-risk neuroblastoma]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dimethyl fumarate (relapsing remitting multiple sclerosis) –Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dimethyl fumarate (psoriasis) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dimethyl fumarate - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2012     Andalusian Health Technology Assessment Area (AETSA) [Digital tomosynthesis of the breast]
2018     Andalusian Health Technology Assessment Area (AETSA) [Digital tomosynthesis in breast cancer: meta-analysis]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Digital tomosynthesis for the diagnosis of breast cancer]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Digital tomosynthesis for breast cancer]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Digital technology promoting health for children and adolescents]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Digital screening mammography. Critical analysis of the article by Chiarelli (2013) and literature review]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Digital mammograms in breast cancer screening. Assessment of their efficiency and inclusion in the Early Breast Cancer Detection Programme of the Basque Country]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Digital interventions - Evidence report on the S3 guideline "Cannabis-related disorders"]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Digital hearing aid in comparison with analog hearing aid for presbycusis: evaluation of the clinical effectiveness and the cost-effectiveness]
2022     Health Sciences Institute in Aragon (IACS) [Digital dermatoscopy]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Digital dermatoscopy for dysplastic nevi]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Digital breast tomosynthesis]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Digital Breast Tomosynthesis]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Differential diagnostic of the burnout syndrome]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Different antihypertensive drugs as first-line therapy in patients with essential hypertension]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Difelikefalin (pruritus) - Benefit assessment according to §35a Social Code Book V]
2013     The Swedish Council on Health Technology Assessment (SBU) [Dietary treatment of obesity]
2010     The Swedish Council on Health Technology Assessment (SBU) [Dietary treatment of diabetes]
2000     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Dietary guidance in the primary health care sector (co-funded by DIHTA)]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Dielectric radiofrequency for the treatment of primary hyperhidrosis and bromhidrosis]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Diamine oxidase activity test for histamine intolerance]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Dialysis in chronic renal failure - a health technology assessment]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnostics and treatment of provoked vestibulodynia]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Diagnostic value of novel biomarkers in patients with chest pain of suspected cardiac origin]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Diagnostic value of an innovative non-invasive diagnostic to determine the grade of atherosclerosis before sternotomy in patients scheduled for cardiac surgery]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Diagnostic usefulness of brain FDG-PET for Alzheimer's dementia]
2019     National Committee for Technology Incorporation (CONITEC) [Diagnostic tests for thrombophilia in pregnancy]
2002     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Diagnostic radiology using transportable equipment]
2008     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Diagnostic performance of techniques used for HER-2 testing in breast cancer]
2009     Andalusian Health Technology Assessment Area (AETSA) [Diagnostic performance of digital mammography in breast cancer screening]
2008     Andalusian Health Technology Assessment Area (AETSA) [Diagnostic performance of clinical prediction models for pulmonary embolism]
2014     The Swedish Council on Health Technology Assessment (SBU) [Diagnostic imaging in the staging of prostate cancer]
2014     The Swedish Council on Health Technology Assessment (SBU) [Diagnostic imaging in suspected prostate cancer]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Diagnostic evaluation and treatment of dementia – a health technology assessment]
2005     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic effectiveness, security and clinical usefulness of capsule endoscopy in the diagnosis of small bowel disorders]
2018     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Diagnostic effectiveness and safety of elastography in liver fibrosis]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Diagnostic colon evaluation in patients with suspected colorectal neoplasia or at high risk of colorectal neoplasia - a comparison of double contrast barium enema (DCBE), CT colonography and colonoscopy]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Diagnostic and therapeutic approach to non complex duodenal ulcer]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy of impulse oscillometry (IOS) compared to spirometry]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy of ex vivo confocal microscopy during Mohs surgery for basal cell carcinomas]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Diagnostic accuracy of anti-CCP antibody test in rheumatoid arthritis: systematic review]
2004     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy and clinical usefulness of Positron Emission Tomography (PET) in breast and ovarian cancer recurrence]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Diagnosis of gestational diabetes mellitus: evaluation of the new IADPSG criteria]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnosis and treatments for epilepsy – a systematic review]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Diagnosis and treatment of obstructive sleep apnoea - a health technology assessment]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Diagnosis and treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in people with Multiple Sclerosis (MS)]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Diagnosis and treatment of chronic cerebrospinal venous insufficiency (CCSVI) for people with multiple sclerosis]
2013     The Swedish Council on Health Technology Assessment (SBU) [Diagnosis and treatment of ADHD and ASDs (autism spectrum disorders)]